Chinese Medicine: Subsidiary's drugs pass the consistency evaluation of generic drug.

The Chinese pharmaceutical company announced that its wholly-owned subsidiary, Tianfang Pharmaceutical, recently received the approval notice for the supplementary application of enteric-coated sodium diclofenac tablets issued by the National Medical Products Administration. The drug has passed the evaluation of generic drug quality and efficacy consistency. As of the disclosure date of the announcement, the cumulative research and development investment in the consistency evaluation of the drug is about 11.29 million yuan. According to data, the sales of this drug in the three major terminals and six major markets in China in 2025 are estimated to be approximately 114 million yuan, but Tianfang Pharmaceuticals will not sell this drug in 2025.